体质指数与急性心肌梗死患者从替格瑞洛降阶至氯吡格雷的关联:TALOS-AMI 试验的事后分析
该研究为TALOS-AMI随机临床试验的基于BMI的事后分析,纳入韩国32个中心2686例急性心肌梗死PCI术后患者,所有患者先接受阿司匹林+替格瑞洛治疗1个月,稳定后随机分为活性对照组(继续阿司匹林+替格瑞洛)或降阶组(阿司匹林+氯吡格雷)再治疗11个月。主要终点为12个月时心血管死亡、心肌梗死、卒中及BARC 2、3、5型出血的复合终点。结果显示,BMI<28组降阶策略较活性对照显著降低复合终点(4.6% vs 8.3%;aHR 0.54;95%CI 0.39-0.76;P<.001),主要归因于出血并发症减少;BMI≥28组无显著关联(3.3% vs 3.2%;aHR 1.07;95%CI 0.33-3.50;P=.91)。作者认为,在BMI较低的稳定急性心肌梗死患者中,1个月后从替格瑞洛无指导降阶为氯吡格雷与更好的临床结局相关。
要点
- BMI<28的稳定AMI患者,PCI术后1个月从替格瑞洛降阶为氯吡格雷,12个月复合终点4.6% vs 8.3%(aHR 0.54;95%CI 0.39-0.76;P<.001),主要因出血减少。
- BMI≥28的稳定AMI患者,降阶组与活性对照组复合终点3.3% vs 3.2%(aHR 1.07;95%CI 0.33-3.50;P=.91),无显著关联。
- TALOS-AMI事后分析纳入2686例患者(平均年龄60.0岁,男性83.2%),BMI<28组2344例,BMI≥28组342例。
- 作者认为,BMI较低的稳定AMI患者1个月后无指导降阶为氯吡格雷与更好临床结局相关。
适用人群与场景
- 急性心肌梗死经皮冠状动脉介入治疗后,初始接受阿司匹林+替格瑞洛治疗1个月的稳定患者。
- 来自TALOS-AMI试验的32个韩国中心,2686例有BMI数据的患者;平均年龄60.0(11.4)岁,男性2234例(83.2%)。
处置流程与药物剂量
- 所有患者PCI术后接受阿司匹林+替格瑞洛治疗1个月,稳定后随机分为活性对照组(继续阿司匹林+替格瑞洛)或降阶组(阿司匹林+氯吡格雷)再治疗11个月。
- BMI<28的稳定患者,降阶策略(阿司匹林+氯吡格雷)与活性对照相比复合终点显著降低(4.6% vs 8.3%;aHR 0.54;95%CI 0.39-0.76;P<.001)。
- BMI≥28的稳定患者,降阶策略与活性对照相比复合终点无显著关联(3.3% vs 3.2%;aHR 1.07;95%CI 0.33-3.50;P=.91)。
研究设计与关键结果
- 研究类型:TALOS-AMI随机临床试验的基于BMI的事后分析;样本量2686例(BMI<28组2344例,降阶组1161例、活性对照组1183例;BMI≥28组342例,降阶组184例、活性对照组158例);32个韩国中心。
- 主要终点为12个月时心血管死亡、心肌梗死、卒中及BARC 2、3、5型出血的复合终点。
- BMI<28组:降阶策略53例(4.6%)vs 活性对照98例(8.3%);aHR 0.54;95%CI 0.39-0.76;P<.001,主要归因于出血并发症减少。
- BMI≥28组:降阶策略6例(3.3%)vs 活性对照5例(3.2%);aHR 1.07;95%CI 0.33-3.50;P=.91。
证据类型、等级与局限
- 证据类型:随机临床试验(TALOS-AMI)的事后分析。
- 试验注册号:ClinicalTrials.gov NCT02018055。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在BMI较低的稳定急性心肌梗死患者中,1个月后从替格瑞洛无指导降阶为氯吡格雷与更好的临床结局相关。
- BMI≥28的稳定患者中,降阶策略与活性对照相比复合终点无显著差异(aHR 1.07;95%CI 0.33-3.50;P=.91)。
指南或共识出处
- TALOS-AMI(Ticagrelor vs Clopidogrel in Stabilized Patients With Acute Myocardial Infarction)随机临床试验;JAMA Network Open。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The potential benefits of P2Y12 inhibitor deescalation for acute myocardial infarction after percutaneous coronary intervention may be influenced by body mass index (BMI).
OBJECTIVES: To investigate the association of BMI on deescalation outcomes after 12 months in patients with acute myocardial infarction after percutaneous coronary intervention who were initially treated with aspirin plus ticagrelor for 1 month, and to assess whether BMI-based switching from aspirin plus ticagrelor (active control strategy) to aspirin plus clopidogrel (deescalation strategy) is associated with individualized benefits.
DESIGN, SETTING, AND PARTICIPANTS: This study is a post hoc analysis, based on BMI, of data from the TALOS-AMI (Ticagrelor vs Clopidogrel in Stabilized Patients with Acute Myocardial Infarction) randomized clinical trial. Data were collected from February 14, 2014, to December 31, 2018, with follow-up to January 21, 2021. Analyses were conducted from December 1, 2021, to August 21, 2024. Among 2697 trial participants from 32 centers in South Korea, 2686 participants whose BMI data were available were included.
EXPOSURE: All patients received aspirin plus ticagrelor for 1 month after percutaneous coronary intervention. Stabilized patients were then randomized to either the active control or deescalation strategy for an additional 11 months.
MAIN OUTCOMES AND MEASURES: The primary end point was a composite of cardiovascular death, myocardial infarction, stroke, and Bleeding Academic Research Consortium bleeding type 2, 3, or 5 at 12 months after percutaneous coronary intervention. The trial compared the active control and deescalation strategies according to BMIs, including an interaction test.
RESULTS: Of the 2686 patients included (mean [SD] age, 60.0 [11.4] years; 2234 [83.2%] male), 2344 (1161 in the deescalation group and 1183 in the active control group) had a BMI less than 28, and 342 (184 in the deescalation group and 158 in the active control group) had a BMI of 28 or greater. The deescalation strategy was associated with significantly reduced composite outcomes compared with the active control strategy in the group with a BMI less than 28 (53 [4.6%] vs 98 [8.3%]; adjusted hazard ratio, 0.54; 95% CI, 0.39-0.76; P < .001), primarily due to fewer bleeding complications. There was no association in the group with a BMI of 28 or greater (6 [3.3%] vs 5 [3.2%]; adjusted hazard ratio, 1.07; 95% CI, 0.33-3.50; P = .91).
CONCLUSIONS AND RELEVANCE: In this post hoc analysis of the TALOS-AMI randomized clinical trial, in stabilized patients with acute myocardial infarction, an unguided deescalation strategy of switching from ticagrelor to clopidogrel after 1 month was associated with better clinical outcomes in those with lower BMIs.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02018055.
参考来源
- Bu S, Kim CJ, Lim S, et al. BMI and Deescalation From Ticagrelor to Clopidogrel in Patients With Acute Myocardial Infarction: A Post Hoc Analysis of the TALOS-AMI Trial. JAMA Netw Open. 2025. PMID: 40014346. doi:10.1001/jamanetworkopen.2024.61916
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。